What's the difference between Foundayo (Orforglipron) and Wegovy injections and tablets (Semaglutide)?
The short answer: both act on the same target, the GLP-1 receptor, so this is a comparison of molecule and delivery rather than mechanism. For weight loss, semaglutide (Wegovy) is available in the UK now, as a weekly injection and as a daily tablet. Orforglipron is under MHRA review.
The distinction that matters day to day: the Wegovy tablet needs a fasting window and strict water rules, whereas the Wegovy injection and orforglipron tablets don't.
Orforglipron vs semaglutide at a glance
How orforglipron and semaglutide work
Both semaglutide and orforglipron activate GLP-1 receptors, reducing appetite, slowing stomach emptying and helping you feel fuller for longer. On mechanism, there's little to separate them.
The difference is structural. Semaglutide is a peptide, a short protein chain. Stomach acid breaks peptides down, which is why semaglutide was introduced as an injection. The newer Wegovy tablet works around this using an absorption technology called SNAC, but that only functions on an empty stomach, which is where the timing rules come from.
Orforglipron is a small molecule, not a peptide. It survives digestion without help, which is why it can be taken at any time of day, with or without food.
Sharing a receptor target doesn't mean equal performance. Formulation, dose and delivery all affect real-world outcomes.
Weight loss comparison of both orforglipron and semaglutide
No head-to-head trial exists. Figures come from separate programmes with different participants and durations.
- Orforglipron: around 11–12% average weight loss at the highest dose over roughly 72 weeks in the pivotal ATTAIN trial, versus ~2% on placebo. Nearly 60% lost at least 10% of their starting weight.
- Semaglutide 2.4mg injection: approximately 15% average weight loss at 68 weeks in STEP 1.
- Wegovy tablets (based on patients reaching the 25mg dose): 13.6% average across all participants over 64 weeks, or 16.6% for those who took it consistently throughout.
What this means in practice
The gap between orforglipron (Foundayo) and semaglutide (Wegovy) is narrower than between orforglipron (Foundayo) and tirzepatide (Mounjaro), which makes this a more genuinely open comparison.
However, no oral GLP-1 has yet matched injectable semaglutide in a head-to-head trial, and populations, designs, and durations still differ, so percentages are directional rather than definitive. Convenience should not be assumed to come without any efficacy trade-off.
Individual results vary and depend on dose, consistency, diet and physical activity. Both are treatment aids used alongside lifestyle change.
Side effects: Foundayo vs Wegovy
The side effects of orforglipron (Foundayo) and semaglutide (Wegovy) are very similar, which is expected given they act on the same receptor. Both are associated mainly with gastrointestinal side effects including nausea, vomiting, diarrhoea, constipation and indigestion, mostly noticeable during phases of increasing dose.
Both carry the same class warnings around thyroid, pancreatitis, gallbladder disease and dehydration.
Also note that because the mechanisms are the same, anyone switching between them in future (from semaglutide to orforglipron) shouldn't expect a meaningfully different tolerability profile, though this hasn't been directly studied.
Seek urgent medical advice if you have: severe or persistent abdominal pain (possible pancreatitis), signs of dehydration, or an allergic reaction.
Dosage scheduling and titration differences
This is where the real difference sits.
Orforglipron is taken once daily, any time, with or without food, which is a meaningful convenience advantage over existing oral GLP-1 options. Steps up at intervals of at least 30 days, starting at 0.8mg and titrating up to 17.2mg.
Wegovy injection is once weekly, starting at 0.25mg and escalating to 2.4mg over roughly 16 weeks. No food or timing rules.
Wegovy tablets are to be taken once daily, first thing, on an empty stomach with a sip of water, then a 30-minute wait before eating, drinking anything else, or taking other medicines.
That last routine is manageable for many people but genuinely difficult for some, e.g. early shifts, unpredictable mornings, or a stack of other morning medications. Orforglipron is specifically designed to avoid it. Convenience matters, but it does not automatically outweigh efficacy, availability, and clinical suitability.
Are they both available in the UK: one is available now, the other is one to watch
Semaglutide is available now, both as the Wegovy weekly injection and as Wegovy tablets, which were approved by the MHRA on 11 June 2026 and became available via private prescription in July. NICE recommends semaglutide for NHS use at thresholds narrower than the licensed indication.
Orforglipron is not. FDA-approved in the US on 1 April 2026, under MHRA review here, with private availability realistically expected in autumn 2026.
FAQ: common questions about orforglipron and semaglutide
Is orforglipron available in the UK?
No, it is under MHRA review, not yet prescribable.
Is orforglipron the same as Wegovy?
No. Different manufacturers, different molecules. Both act on GLP-1 receptors, but orforglipron is a small molecule and semaglutide is a peptide.
Does orforglipron work better than semaglutide?
No head-to-head trial exists. On separate trials semaglutide has shown somewhat greater average weight loss, though the gap is narrower than with tirzepatide.
Will a weight loss pill replace injections like Wegovy?
For some people, yes, particularly those who've avoided treatment because of needles. But on current evidence oral options haven't outperformed injectables.
I want an oral option now, what can I do?
The Wegovy tablet is licensed and available today. It requires a fasting window and strict water rules, but it's an approved oral route you don't have to wait for.
References
Clinical trial data
- Lilly ATTAIN-1 trial — orforglipron in adults with obesity without type 2 diabetes (72-week weight loss data, 12.4% mean body weight reduction).
- Lilly ATTAIN-2 trial — orforglipron in adults with obesity and type 2 diabetes (72-week weight loss data, 10.5% mean body weight reduction).
- STEP 1 trial — semaglutide 2.4mg in adults with obesity without type 2 diabetes (68-week data, ~15% mean body weight reduction). Wilding et al., NEJM 2021.
- STEP 2 trial — semaglutide 2.4mg in adults with obesity and type 2 diabetes (~10% mean body weight reduction). Davies et al., Lancet 2021.
Regulatory and NICE guidance
- NICE Technology Appraisal TA875 — semaglutide (Wegovy) for managing overweight and obesity in adults.
- NHS England interim commissioning policy and phased access guidance for semaglutide (Wegovy).
- MHRA product information for Wegovy (semaglutide 2.4mg).
- MHRA product information for Ozempic (semaglutide 1mg, type 2 diabetes indication).
Lilly press and trial materials
- Lilly investor and press releases for ATTAIN-1 and ATTAIN-2 trial results (2024–2025).
- Lilly ACHIEVE programme background materials describing orforglipron as an oral small-molecule GLP-1 receptor agonist.
- Lilly regulatory submission timeline statements for orforglipron.
NHS and clinical prescribing references
- NHS summary of product characteristics for Wegovy — dose escalation schedule from 0.25mg to 2.4mg.
- NHS summary of product characteristics for Rybelsus — fasting administration requirements.
- NICE TA875 eligibility criteria (BMI thresholds, comorbidity requirements, specialist referral pathway).
